These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10765033)

  • 21. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.
    Ito A; Kohira N; Bouchillon SK; West J; Rittenhouse S; Sader HS; Rhomberg PR; Jones RN; Yoshizawa H; Nakamura R; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2016 Mar; 71(3):670-7. PubMed ID: 26645269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meropenem: a new carbapenem antimicrobial.
    Pryka RD; Haig GM
    Ann Pharmacother; 1994 Sep; 28(9):1045-54. PubMed ID: 7803882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.
    Thomson KS; Moland ES
    J Antimicrob Chemother; 2004 Aug; 54(2):557-62. PubMed ID: 15201229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of ceftobiprole against gram-negative and gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study.
    Cereda RF; Azevedo HD; Girardello R; Xavier DE; Gales AC;
    Braz J Infect Dis; 2011; 15(4):339-48. PubMed ID: 21861004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of biapenem against recent gram-negative and gram-positive clinical isolates.
    Bonfiglio G; Maccarone G; Mezzatesta ML; Privitera A; Carciotto V; Santagati M; Stefani S; Nicoletti G
    Chemotherapy; 1997; 43(6):393-3. PubMed ID: 9395852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
    Eltahawy AT
    J Chemother; 1997 Dec; 9(6):403-10. PubMed ID: 9491839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
    Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
    J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
    Cereda RF; Pignatari AC; Leme IL; Jones RN; Sader HS
    Rev Assoc Med Bras (1992); 1996; 42(3):130-4. PubMed ID: 9138353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.
    Malanoski GJ; Collins L; Wennersten C; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2009-16. PubMed ID: 8239623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial activity of Achillea clavennae essential oil against respiratory tract pathogens.
    Skocibusić M; Bezić N; Dunkić V; Radonić A
    Fitoterapia; 2004 Dec; 75(7-8):733-6. PubMed ID: 15567252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.
    Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.